Related Experiment Videos
Statins provoking MELAS syndrome. A case report.
Joseph E Thomas1, Nora Lee, Paul D Thompson
1Department of Internal Medicine, School of Medicine, University of Connecticut, Farmington, Conn., USA. drjethomas@yahoo.com
European Neurology
|March 29, 2007
Summary
Statins can trigger mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in susceptible individuals by inhibiting coenzyme Q10 (CoQ10) production. This highlights a potential risk of statin therapy in patients with underlying mitochondrial disorders.
Area of Science:
- Biochemistry
- Mitochondrial Medicine
- Pharmacology
Background:
- Statins reduce coenzyme Q10 (CoQ10) levels, a vital component for mitochondrial electron transport.
- Coenzyme Q10 deficiency is linked to mitochondrial encephalomyopathy.
Observation:
- A patient with mitochondrial syndrome experienced symptoms of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS).
- The onset of MELAS symptoms correlated with the initiation of statin therapy.
Findings:
- Statin use may precipitate or exacerbate MELAS symptoms in genetically predisposed individuals.
- The mechanism involves statin-induced inhibition of CoQ10 synthesis, impairing mitochondrial function.
Implications:
- Clinicians should consider CoQ10 levels and mitochondrial health in patients prescribed statins.
- This case underscores the importance of recognizing potential drug-induced mitochondrial toxicity.
- Further research is warranted to elucidate the precise relationship between statins and MELAS.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...